BDNF and cancer: The multimodal pharmacological activity of vortioxetine targeting neurotransmitter receptors may selectively modulate, for instance, BDNF-related signaling pathways in the brain, including PI3 kinase-Akt-mTOR signaling, without promoting cancer peripherally, or interfering with the anti-cancer efficacy of ADT.